Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 9/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.34 |
| ▸ | MMP13 | P45452 | 1/20 | 0.34 |
| ▸ | MMP14 | P50281 | 1/20 | 0.34 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.34 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | ALPL | P05186 | 1/20 | 0.33 |
| ▸ | ALPI | P09923 | 1/20 | 0.33 |
| ▸ | ALPG | P10696 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2502266 | 0.83 | MAOA (0.42) | GPR119HDAC6MMP2MMP13MMP14 | |
| SCHEMBL2507043 | 0.83 | GPR119 (0.41) | GPR119MMP2MMP13MMP14ADAMTS5 | |
| SCHEMBL2499942 | 0.82 | GPR119 (0.39) | GPR119 | |
| SCHEMBL2480377 | 0.82 | GPR119 (0.40) | GPR119MMP2MMP13MMP14ADAMTS5 | |
| SCHEMBL2498576 | 0.82 | HPGD (0.39) | GPR119LMNAALDH1A1MAPT | |
| SCHEMBL2452755 | 0.79 | MAOA (0.40) | GPR119ALKMMP2MMP13MMP14 | |
| SCHEMBL2503392 | 0.78 | GPR119 (0.37) | GPR119ALKMMP2MMP13MMP14 | |
| SCHEMBL2486343 | 0.77 | GPR119 (0.37) | GPR119MMP2MMP13MMP14ADAMTS5 | |
| SCHEMBL2501461 | 0.77 | MAOA (0.38) | GPR119ALK | |
| SCHEMBL2480116 | 0.77 | ALDH1A1 (0.37) | GPR119LMNAALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841306-B2 | Antimicrobials | PANACEA BIOTEC LTD. (IN) | 2014-09-23 | — | — | US | disclosed |
| US-20110245258-A1 | NOVEL ANTIMICROBIALS | PANACEA BIOTEC LTD. (IN) | 2011-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245258-A1 | NOVEL ANTIMICROBIALS | ECI1, XDH, CYP3A4 | GPR119 2490/4885HDAC6 281/4885ALK 2464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.